Cancer Immunotherapy Guidelines-Melanoma

The first evidence-based consensus statement on tumor immunotherapy for the treatment of patients with melanoma was released by the Society for Immunotherapy of Cancer (SITC) and published online by Nature Reviews Clinical Oncology in 2013.

"The Society for Immunotherapy of Cancer Consensus Statement on Tumor Immunotherapy for the Treatment of Cutaneous Melanoma," offers a road map for using immunotherapy to treat patients with melanoma.

This consensus statement provides patients and physicians with expert evidence-based recommendations for the use of immunotherapies including interferon-α2, pegylated interferon, interleukin-2 (IL-2) and ipilimumab. This statement includes recommendations for patient selection, toxicity management, clinical end points, and sequencing or combination of therapies.

The Melanoma Research Foundation worked directly with SITC leadership to create an educational video about the Guidelines, published in 2013.

Cancer Immunotherapy Guidelines-Melanoma

Melanoma Guidelines Update

The Cancer Immunotherapy Guidelines-Melanoma manuscript is currently being updated. All members of the 2011 – 2013 Task Force and Steering Committee, as identified below, have returned to lead this project.

Steering Committee

Howard L. Kaufman, MD, FACS, Committee Chair – Rutgers Cancer Institute of New Jersey
Michael B. Atkins, MD – Georgetown-Lombardi Comprehensive Care Center
Stephen Hodi, Jr., MD – Dana-Farber Cancer Institute
John M. Kirkwood, MD – University of Pittsburgh

Task Force

Sanjiv Agarwala, MD St. Luke´s Cancer Center	Thomas Amatruda, MD Humphrey Cancer Center	Steven Bines, MD Rush University Medical Center
Joseph I. Clark, MD Loyola University Medical Center	Brendan Curti, MD Providence Cancer Center	Marc Ernstoff, MD Dartmouth-Hitchcock Medical Center
Thomas Gajewski, MD, PhD University of Chicago Medical Center	Rene Gonzalez, MD University of Colorado Denver	Patrick Hwu, MD MD Anderson Cancer Center
Laura Jane Hyde Gilda's Club	David Lawson, MD Emory Winship Cancer Institute	Mike Lotze, MD University of Pittsburgh
Jose Lutzky, MD Mt. Sinai Comprehensive Cancer Center	Kim Margolin, MD University of Washington School of Medicine	Dave McDermott, MD Beth Israel Deaconess Medical Center
Donald Morton, MD John Wayne Cancer Institute	Anna Pavlick, DO New York University	Jon M. Richards, MD, PhD Lutheran General Hospital Advanced Care Center
Douglas Schartzentruber, MD Goshen Center for Cancer Care	Bill Sharfman, MD Johns Hopkins University	Vernon Sondak, MD H. Lee Moffitt Cancer Center and Research Institute
Jeff Sosman, MD Vanderbilt-Ingram Cancer Center	Susan Steel Skin of Steel (Melanoma Patient Advocacy for Chicago)	Ahmad Tarhini, MD University of Pittsburgh
John Thompson, MD University of Washington School of Medicine	Jill Titze, RN, NP Rush University Medical Center	Walter Urba, MD, PhD Providence Cancer Center
Richard White, Jr., MD Carolinas Medical Center

Cancer Immunotherapy Guidelines-Melanoma

Cancer Immunotherapy Guidelines-Melanoma

Melanoma Guidelines Update

Steering Committee

Task Force

Membership Links

Get Involved